Lupin announced the completion of an inspection carried out by the United States Food and Drug Administration (USFDA) at its Vizag API manufacturing facility. The inspection was carried out between 13 January 2020 and 17 January 2020. The inspection for the API facility at Vizag closed with five 483 observations.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
